$ONCO News

Last published 3d ago

3d agoXBOTF ONCORealbotix Provides Update on Nasdaq Listing TimelineBusiness WireLAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a manufacturer of humanoid robots and AI systems, announces that it has extended the outside date for completion of its all-stock merger transaction between Realbotix LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix, and Onconetix, Inc. (NASDA ...
3d agoONCOTrading halt: Onconetix, Inc. Common Stock (ONCO), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-09 10:00:49.960 ET, resumption quote 2026-11-09 10:00:49 ET, resumption trade none.
3d agoONCOTrading halt: Onconetix, Inc. Common Stock (ONCO), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-09 09:50:58.203 ET, resumption quote 2026-11-09 09:50:58 ET, resumption trade none.
1w agoONCOTrading halt: Onconetix, Inc. Common Stock (ONCO), News pendingNasdaq Trading HaltsHalted 2026-11-05 19:50:00.000 ET, resumption quote none, resumption trade none.
2w agoONCOOnconetix Announces Reverse Stock SplitGlobeNewswireCINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company"), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the
3mo agoONCOOnconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AGGlobeNewswireProteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc.
5mo agoONCOOnconetix, Inc. Announces 1-for-10 Reverse Stock SplitGlobeNewswireCINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of
6mo agoONCOOnconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyGlobeNewswireNew Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances
7mo agoONCOOnconetix, Inc. Announces 1-for-5 Reverse Stock SplitGlobeNewswireCINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization
9mo agoONCOOnconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics CompanyGlobeNewswireA leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc.,
1y agoGTBP IMAB ENGN ONCO+1Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment ParadigmsPR NewswireEquity InsiderNews Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are...
1y agoONCOOnconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.GlobeNewswireCINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc.
1y agoONCOJoint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger AgreementGlobeNewswireCINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc.
1y agoONCOOnconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTMGlobeNewswireCINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization
1y agoONCOOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementGlobeNewswireCINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development
1y agoONCOOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelGlobeNewswireCINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of
1y agoONCOOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersGlobeNewswireCINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of
1y agoONCOOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqGlobeNewswireCincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on May 20, 2025 indicating
1y agoONCOOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqGlobeNewswireCincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on April 24, 2025
1y agoONCOOnconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.GlobeNewswireCINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held
1y agoONCOOnconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohortGlobeNewswireCINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research,
1y agoONCOOnconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology CongressGlobeNewswireCINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research,
1y agoONCOOnconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent FilingGlobeNewswireCincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a letter from The Nasdaq Capital Market ("Nasdaq") on December 6, 2024 indicating that the
2y agoENTO OCS ONCO VRNAVirometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the BoardBusiness WireVirometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today
2y agoONCOCorrection: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditGlobeNewswireCINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (NASDAQ:ONCO), please note that in the first paragraph of the release, the name of the
2y agoONCOOnconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditGlobeNewswireCINCINATTI, Oh., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or "the Company") (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research,
2y agoONCOOnconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of StockholdersGlobeNewswireCINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of
2y agoONCOOnconetix Announces Closing of Warrant Exercise for $1.11 Million Gross ProceedsGlobeNewswireCINCINNATI, July 15, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. ("Onconetix" or the "Company") (NASDAQ:ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase
2y agoONCOOnconetix Announces Exercise of Warrants for $1.11 Million Gross ProceedsGlobeNewswireCINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. ("Onconetix" or the "Company") (NASDAQ:ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing
2y agoONCOOnconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of DirectorsGlobeNewswireCINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial stage biotechnology company focused on developing and commercializing therapeutics,
2y agoBWV ONCOBlue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™GlobeNewswireCINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology
4y agoONCOOncopeptides provides an update from the meeting with FDAs advisory committee ODACPR NewswireSTOCKHOLM, Sept. 23, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ:ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Oncologic Drugs
4y agoONCOBriefing Book for ODAC meeting on benefit/risk profile of Pepaxto now publishedPR NewswireSTOCKHOLM, Sept. 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ:ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug
4y agoONCOOncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myelomaPR NewswireSTOCKHOLM , Sept. 7, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ:ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company has rece
4y agoONCOOncopeptides publishes the 2021 Annual ReportPR NewswireSTOCKHOLM, April 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ:ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the 2021 Annual Repor
5y agoONCOOncopeptides submits application for conditional marketing authorization of melflufen in the EUPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network®PR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice GuidelinesPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides announces that the first patients in the United States are being treated with PEPAXTO®PR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)PR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myelomaPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOFDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple MyelomaPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOFDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myelomaPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...
5y agoONCOOncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myelomaPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating...
5y agoONCOOncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor RelationsPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
5y agoONCOFull data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical OncologyPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
5y agoONCOOncopeptides will host a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meetingPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
5y agoONCOOncopeptides presents new data from phase 2 ANCHOR combination study in multiple myeloma at American Society of Hematology meeting ASHPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
5y agoONCOProgram for Oncopeptides virtual Capital Markets Day on November 30 is publishedPR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
6y agoONCOOncopeptides hosts a virtual capital markets day on November 30PR NewswireOncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts...